MicroPort CardioFlow Completes Acquisition of Cardiac Rhythm Management Group
MicroPort CardioFlow Medtech Corporation has completed its acquisition of MicroPort Cardiac Rhythm Management Limited and its subsidiaries, which are now indirect subsidiaries of the company. The transaction was finalized on December 19, 2025, following the satisfaction or waiver of all conditions precedent under the merger agreement. With this completion, the company expands its business scope from interventional treatment of structural heart diseases to include cardiac rhythm management, establishing a diversified product platform in the Total Cardio field. The integration is expected to enhance the group’s global market presence, competitiveness, and risk resilience, while enabling the delivery of comprehensive management solutions for heart failure across all causes and stages of the disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251221-11962656), on December 21, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。